Track the 셀트리온 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 셀트리온 has published 467 insider filings. Market capitalisation: €41,622.9bn. The latest transaction was reported on 16 July 2026 (Purchase). Among the most active insiders: 셀트리온홀딩스. Every trade is openly available.
461
Insider Decl.
n/a
Thresholds
€17m
189 ops.
Buy Volume
€68m
59 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 셀트리온 Buy (bullish), based on 24 analysts. Average price target: ₩265,216.
22Σ signal
Buys €17m€68m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,516 of 28,169 companies
49.1
score / 100
Value
33
Quality
65
FCF yld0.7%
Earn yld2.3%
EV/EBITDA32.6x
ROE7.3%
Gross mgn59%
Net mgn25%
Debt/EBITDA2.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Celltrion is a South Korean company focused on the development and manufacturing of biosimilar drugs and innovative therapies. It is listed on the Korea Exchange, XKRX.